Bedrocan International's Exciting Return to Canada
Bedrocan International, a globally recognized leader in pharmaceutical-grade medicinal cannabis production, is making a significant comeback in the Canadian medicinal cannabis market. The company has successfully acquired a facility in a well-known area, which marks its re-entry and has been granted a cultivation license by Health Canada. With this strategic move, Bedrocan is fulfilling a long-standing commitment to provide standardized medicinal cannabis for patients in Canada, planning to kick off production in early 2025.
Company Commitment to Quality Medicinal Cannabis
Focusing exclusively on the production of medicinal cannabis, Bedrocan is committed to delivering high-quality cannabis products that maintain consistent levels of THC and CBD. According to Bedrocan's CEO, Jaap Erkelens, their approach has always been strictly pharmaceutical. He emphasizes the importance of using the extensive knowledge acquired over two decades to create cannabis products that serve the needs of patients. His insights reveal a vital aspect of the company's philosophy: much like physicians, patients want a reliable and standardized product that provides consistent therapeutic effects.
Standardized Cannabis Products for Health Care
Bedrocan plans to introduce a range of standardized cannabis products aimed at enhancing patient care. The flagship product, known widely as Bedrocan®, will be among the first to reach the market. Distribution will be facilitated through a reputable third party, concentrating on the medical sales channel to ensure that registered patients have access to these vital products.
Looking Back: Bedrocan's Past in Canada
Bedrocan has a history in Canada but found its operations disrupted following the end of a partnership with Canopy Growth. Despite this setback, the company has remained steadfast in its intent to return. CEO Jaap Erkelens expressed excitement about the comeback, stating, "We are thrilled to be coming back and are eager to positively impact the Canadian healthcare landscape. Our focus will always be on supporting patients and providing them with the highest quality products available."
Frequently Asked Questions
What is Bedrocan's primary focus?
Bedrocan is dedicated to producing standardized medicinal cannabis products specifically for patients.
When does Bedrocan plan to start production in Canada?
Bedrocan intends to commence production in early 2025.
How does Bedrocan ensure product consistency?
The company applies rigorous pharmaceutical standards to maintain consistent levels of THC and CBD in their cannabis products.
Will Bedrocan distribute products directly to patients?
No, Bedrocan will work through a third-party distributor to ensure access via medical sales channels for registered patients.
Why is Bedrocan returning to Canada?
The company aims to fulfill its commitment to Canadian patients and contribute positively to the local healthcare landscape.
